BONS Share Price Performance
₪0.26
0.12 (89.13%)
Price ₪0.26
Share Price₪0.26
BONS Community Narratives
There are no narratives available yet.
Recent BONS News & Updates
No updates
Bonus BioGroup Ltd. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.024
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Bonus BioGroup Ltd. Competitors
About BONS
- Founded
- 1981
- Employees
- 49
- CEO
- WebsiteView website
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company’s products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel.
Israeli Market Performance
- 7 Days: -1.7%
- 3 Months: 18.6%
- 1 Year: 67.6%
- Year to Date: 27.4%
Over the last 7 days, the market has dropped 1.7%, driven by losses in the Financials and Real Estate sectors of 1.8% and 2.9%, respectively. In the last year, the market is actually up 68%. Earnings are forecast to grow by 16% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading